远大医药(00512.HK)收购香港东海医疗余下股本权益
远大医药(00512.HK)公布,公司与东海资本(香港)有限公司订立了股份购买协议,同意收购香港东海医疗有限公司(目标公司)的752股股份,代表目标公司全部已发行股本的约50.13%,代价为1,200万美元。
待完成股份购买协议後,目标公司将会成为公司之全资拥有附属公司。
公司指,目标公司之主要资产为於Conavi之股权投资,及「Novasight Hybrid」系列及「Foresight ICE」系列等产品在中国大陆、香港、澳门及台湾等地区之二十年独家代理权。
公司管理层认为Conavi之产品已展示美好的前景,而收购目标公司余下的股本以增加与Conavi的起步阶段所占的份额亦为符合公司的利益,与集团打造国际领先的泛血管精准介入诊疗平台的布局与规划完美契合,有助於集团在精准介入领域实现诊疗一体化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.